1,600 patients, 36 months of follow-up: the OPTION trial showed LAAO superior to OAC for safety and non-inferior for efficacy. Yet, #ESCGuidelines AFib 2024 gave LAAO an IIb (LoE C) indicationWill these findings reshape future recommendations? Let us know your thoughts! 🤔

#EHRAtopicweek #EHRA_ESC @escardio
#ESCGuidelines